All Insights
Showing 1 - 12 of 394
Life Sciences and Healthcare
EU introduces harmonised template for clinical trial recruitment and consent
A single EU-wide structure now governs how sponsors document recruitment and informed consent across all member states
Life Sciences and Healthcare
EU draft guidelines sharpen high-risk AI classification for medtech and digital health
European Commission offers draft guidance on risk classification for medtech, biometrics, triage and health insurance
Artificial intelligence
European Commission publishes draft AI Act guidelines on high-risk classification and targeted consultation
Affected businesses have until 23 July 2026 to suggest changes to the current draft guidelines, and should develop appropriate AI
Knowledge Notes
The UK King's Speech – what can business expect this year?
The government has set out its agenda for the new Parliamentary session, with continued emphasis on economic growth
Life Sciences and Healthcare
US-UK deal reshapes pharma trade and pricing for life sciences businesses
The agreement marks a structural shift in trading conditions, pricing and market access for life sciences companies in both markets
Regulatory Outlook
Products | UK Regulatory Outlook April 2026
UK and EU regulatory and legal developments affecting general and digital, life science and healthcare, and sustainable products, including the
Life Sciences and Healthcare
EU privacy regulators adopt a single data-processing lawful basis for clinical trials
The EDPB and the EDPS back the proposed European Biotech Act but urge stronger safeguards for health and genetic data
Life Sciences and Healthcare
UK clinical trials regulation undergoes its biggest overhaul in 20 years
New framework streamlines approvals and reporting for sponsors while tightening transparency and pharmacovigilance duties
Life Sciences and Healthcare
Belgium tightens food and pharma control with new inter-agency protocol
Regulators strengthen oversight of food supplements, specialised nutrition, medicated feed and veterinary medicines
Life Sciences and Healthcare
Supplements from lab to label: the compliance checklist
From concept and formulation through ingredient due diligence and safety, novel food assessments, claims and advertising, labelling and post‑market surveillance
Life Sciences and Healthcare
EU overhauls pharmaceutical law with sweeping 2026 reform package
Landmark reform overhauls incentives, supply obligations and regulatory pathways for pharmaceuticals operating in Europe
Life Sciences and Healthcare
Nagoya Protocol compliance shapes EU sourcing of genetic resources for R&D
Life sciences, food and cosmetics businesses using biological materials should assess their exposure to ABS obligations
